MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on September 29, 2006; DOI: 10.1124/mol.106.029595


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.029595v1
71/1/38    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sancar, F.
Right arrow Articles by Czajkowski, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sancar, F.
Right arrow Articles by Czajkowski, C.


Received for publication August 7, 2006.
Revised September 27, 2006.
Accepted for publication September 28, 2006.

Structural determinants for high affinity zolpidem binding to GABA-A receptors

Feyza Sancar 1, Spencer S Ericksen 1, Amy M Kucken 1, Jeremy A Teissere 2, Cynthia Czajkowski 1*

1 University of Wisconsin-Madison 2 Muhlenberg College

* Address correspondence to: E-mail: czajkowski{at}physiology.wisc.edu

Abstract

The imidazopyridine zolpidem (Ambien®) is one of the most commonly prescribed sleep aids in the nation (Rush, 1998). Similar to classical benzodiazepines (BZDs), zolpidem binds at the extracellular N-terminal {alpha}/{gamma} interface of the GABA-A receptor (GABAR). However, zolpidem differs significantly from classical BZDs in chemical structure and neuropharmacological properties. Thus, classical BZDs and zolpidem likely have different requirements for high affinity binding to GABARs. To date, three residues {gamma}2M57, {gamma}2F77 and {gamma}2M130, have been identified as necessary for high affinity zolpidem binding (Wingrove et al, 1997; Buhr and Sigel, 1997). Here, we used radioligand binding techniques, {gamma}2/{alpha}1 chimeric subunits ({chi}), site-directed mutagenesis, and molecular modeling to identify additional {gamma}2 subunit residues important for high affinity zolpidem binding. While {alpha}1{beta}2{chi} receptors containing only the first 161 amino-terminal residues of the {gamma}2 subunit bind the classical BZD flunitrazepam with wild-type affinity, zolpidem affinity is decreased ~8 fold. By incrementally restoring {gamma}2 subunit sequence, we identified a 7 amino acid stretch in the {gamma}2 subunit Loop F region (a.a. 186-192) that is required to confer high affinity zolpidem binding to GABARs. When mapped to a homology model, these seven amino acids comprise part of loop F located at the {alpha}/{gamma} interface. Based on in silico zolpidem docking, three residues within loop F, {gamma}2E189, {gamma}2T193, and {gamma}2R194, emerge as being important for stabilizing zolpidem in the BZD binding pocket and likely interact with other loop F residues to maintain the structural integrity of the BZD binding site.


Key words: GABAA, GABAC, Structure-activity relationships and modeling, Func. analysis receptor/ion channel mutants, Benzodiazepines


This article has been cited by other articles:


Home page
J. Neurosci.Home page
S. M. Hanson and C. Czajkowski
Structural Mechanisms Underlying Benzodiazepine Modulation of the GABAA Receptor
J. Neurosci., March 26, 2008; 28(13): 3490 - 3499.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. L. Padgett and S. C. R. Lummis
The F-loop of the GABAA Receptor {gamma}2 Subunit Contributes to Benzodiazepine Modulation
J. Biol. Chem., February 1, 2008; 283(5): 2702 - 2708.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics